AskAt received a Notice of Allowance dated June 8, 2023 from the Korean Intellectual Property Office (KIPO) for an EP4 receptor antagonist use patent in the treatment of cartilage disease. The notice was issued in connection with Korean Patent Application No. 10-2021-7012435 (Filing Date: March 19, 2014) for the use of AAT-007 (grapiprant). AskAt’s EP4 receptor antagonist cartilage disease use patent has already been granted in Japan, the United States, Europe, Canada, China, Korea, Mexico, Russia, and Hong Kong. This expansion grant will reinforce patent protection in Korea.